Roche Diagnostics Corporation
Roche Diagnostics Corporation, a subsidiary of the Swiss multinational Roche Holding AG, is a leading player in the global healthcare industry, headquartered in the United States. Established in 1896, Roche has consistently innovated in diagnostics, focusing on areas such as molecular diagnostics, tissue diagnostics, and point-of-care testing. With a strong presence in North America, Europe, and Asia, Roche Diagnostics is renowned for its cutting-edge products, including the cobas® series of diagnostic systems and the Elecsys® immunoassay platform. These offerings are distinguished by their accuracy, speed, and ability to deliver comprehensive results, making them invaluable in clinical settings. Roche Diagnostics holds a prominent market position, recognised for its commitment to advancing personalised healthcare and achieving significant milestones in diagnostic technology.
DitchCarbon Score
How does Roche Diagnostics Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Roche Diagnostics Corporation's score of 40 is higher than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Roche Diagnostics Corporation, headquartered in the US, currently does not have publicly available data on its carbon emissions, as no specific emissions figures have been provided. Additionally, there are no documented reduction targets or climate pledges outlined in their initiatives. In the context of the diagnostics industry, companies are increasingly focusing on sustainability and climate commitments, often setting ambitious targets to reduce their carbon footprints across all scopes of emissions. While Roche Diagnostics has not disclosed specific commitments or achievements in this area, the industry trend suggests a growing emphasis on environmental responsibility and the adoption of science-based targets to mitigate climate impact. As the company moves forward, it may consider establishing measurable goals to enhance its sustainability profile and align with global climate initiatives.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 319,538,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 320,860,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 209,660,000 | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Roche Diagnostics Corporation is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
